Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. [PDF]
RMD Open, 2019 Lindström U +11 more
europepmc +1 more source
Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]
Adv TherMarotte H +7 more
europepmc +1 more source
A bibliometric analysis of the global research on biosimilars. [PDF]
J Pharm Policy Pract, 2018 Hernández-Vásquez A +4 more
europepmc +1 more source
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. [PDF]
Curr Rheumatol Rep, 2017 Moots R +7 more
europepmc +1 more source
The changing landscape of biosimilars in rheumatology. [PDF]
Ann Rheum Dis, 2016 Dörner T +9 more
europepmc +1 more source
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars. [PDF]
Front PharmacolZeng Z +7 more
europepmc +1 more source
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study [PDF]
Annals of the Rheumatic Diseases, 2017 Houng Kim, Marek Brzosko, Yeon-Ah Lee
exaly +2 more sources